Wells Fargo initiated coverage of BioNTech (BNTX) with an Overweight rating and $170 price target The firm’s deep dive on the PD1/VEGF space puts BioNTech as a fast follower in grabbing a big chunk of a $100B opportunity. Newsflow over the next 12-18 months should provide further upside, Wells says.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BNTX:
- Whitefort Capital sends letter to Arbutus Biopharma board of directors
- BioNTech price target raised to $171.44 from $171 at Canaccord
- BioNTech price target lowered to $122 from $124 at JPMorgan
- Trump Trade: Trump Media considers developing crypto payment service
- Trump expected to pick Martin Makary to head FDA, Reuters reports